Recent headlines in health news spotlight several pharmaceutical developments: AbbVie's Parkinson's drug shows promise in ...
The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.
Researchers at the Foundation have uncovered new insights into the complex link between dopamine and rest tremor in Parkinson ...
This report offers insights into recent health news, encompassing advancements in Parkinson's and cancer treatments, ...
Kim Benda, who sought to challenge incumbent Mayor Mike Parkinson, was removed from the ballot on Monday morning after her petition papers were found to be unbound — a technical violation that ...
AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson's disease on Monday and said it's on track to seek approval for the drug from the Food and Drug ...
AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on ...
AbbVie reports Phase 3 TEMPO-2 trial success for tavapadon, a once-daily Parkinson's treatment, showing significant symptom ...
Tavapadon hit the primary endpoint in one phase 3 trial in April, before AbbVie closed the takeover, and racked up another victory in September. AbbVie completed the set Monday by reporting data from ...
J.P. Morgan 2025 Healthcare Conference, taking place January 13–16, 2025, in San Francisco, CA ...
The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.
Intra-Cellular Therapies is developing Lenrispodun for the treatment of patients with Parkinson's Disease in a phase 2 study.